PTC THERAPEUTICS, INC.
Company Stats
- Market Cap
- $5.4B
- as of Sep 30, 2026
- Shares Outstanding
- 83.5M
- Free Float
- 94.7%
Income Statement
- Revenue
- $1.7B
- Operating Income
- $866.9M
- Net Income
- $682.6M
- EBITDA
- $905.8M
- Revenue Growth, 3Y
- 35.3%
- FCF Margin, 3Y Avg
- 2.2%
- FCF Margin, Worst Year
- -19.9%
Cash Flow
- Free Cash Flow
- $702.3M
- FCF Yield
- 13.0%
- Owner FCF Yield
- 11.6%
Balance Sheet
- Cash & Equivalents
- $984.6M
Returns & Capital
- SBC, 3Y Avg
- $83.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $1.7B | $702.3M | 40.6% |
| FY2024 | $806.8M | -$114.2M | -14.2% |
| FY2023 | $937.8M | -$186.9M | -19.9% |
| FY2022 | $698.8M | -$388.7M | -55.6% |
| FY2021 | $538.6M | -$279.5M | -51.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 9, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
November 1, 2026
Weekly Earnings
Micro-Cap Earnings Roundup for Week of Oct. 26, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 22, 2026
Deals
PTC Completes ST-920 Fabry Gene Therapy Purchase
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
Micro-Cap Earnings Roundup for Week of Oct. 26, 2026
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 22, 2026
Deals
PTC Completes ST-920 Fabry Gene Therapy Purchase
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back